CLINICAL_TRIALS
trial_result
· 2017-04-04
Clinical Trial Update: Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin [Phase 3]
Summary
Phase 3 study assessing the feasibility of once-daily lixisenatide in combination with basal insulin in type 2 diabetes, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Medical University of Vienna | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2017-04-04